By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Tuesday that its board of directors has authorized a $100 million stock repurchase program.
The latest buyback is the firm's third $100 million share repurchase program.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.